Pharmaceutical Executive, Jan 1, 2013 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Jan 1, 2013
Features
The Scoop on Drug Shortages
By Kenneth Getz , Mary Jo Lamberti
New research sheds fresh light on a trend with serious consequences for the public health—not only in the United States but for patients worldwide.
Compliance in the C-Suite
By Ben Comer
Compliance officers have risen into management's highest ranks, by choice in some organizations, and by government decree in others. Either way, their importance as a strategic partner can hardly be understated.
The Permanent Campaign
By William Looney
Promoting the merits of private-sector drug innovation is no easy task—just ask the UK's Office of Health Economics, with a record 50 years of engagement around the hard policy questions that ultimately drive success in the pharmaceutical marketplace.
Industry Forecast 2013
By William Looney
As companies seek safety from empowered payers, bankrupt governments, and distracted regulators, success will come to those who understand how competition and technology are changing the way everything this industry does.
Country Report
Country Report: Singapore
Most executives across the pharmaceutical industry agree—Singapore does not represent any question marks in the future. Furthermore, Singapore's location is ideal for reaching markets east, west, north and south, which form the powerhouse that is Asia-Pacific.
Column
Who Lost Syria?
By Clark Herman
Thankfully, the civil war is not a public relations issue for Big Pharma, but the long-term business implications for the Middle East region are cagey.
The Doctor-Patient Disconnect
By Al Topin
Doctor-patient conversations aren't always what we think—this basic interaction represents both a problem and an opportunity for today's drug marketers, writes Al Topin.
Product Liability Claims and Comment K
Courts across the country are making it easier to prove that a drug is unsafe, warning label notwithstanding.
The Force Behind Sales Forces
By Torsten Bernewitz
Don't underestimate the importance of the first line manager.
Transformation to Characterize 2013
By Jill Wechsler
FDA policies will reshape drug development, while pressure to cut healthcare spending may alter drug coverage and pricing.
From the Editor
The Long Swim—Upstream
By William Looney
2013 may be a number associated with the fate of the luckless, but our annual review of the business and policy environment for Big Pharma suggests otherwise—as we near the midway point in the "tween" decade, there is good fortune in store for those with the perspective that comes with the long view.

ADVERTISEMENT

Click here